According to the associated press, gunshots rang out near the government building in Kiev, Ukraine.

China's First Oral COVID-19 Antiviral Medicine in Dispute

An obscure Chinese company called Genuine Biotech(Chinese: 真实生物) was suddenly put under the spotlight on July 25 when the Chinese authority announced the conditional approval of the company's application for adding the treatment of COVID-19 as a new indication of Azvudine under the special review and approval procedures for drug registration.

HONOR (荣耀) Registers 19% YoY Growth in Q1 2026, Ranking First in Growth Speed Among Global Top 10 Smartphone OEMs According to Omdia

HONOR (荣耀) achieved a 19% YoY increase in Q1 2026 global smartphone shipments to 19.2 million units, leading top ten OEMs in growth rate by leveraging an explosive premium expansion across the Middle East, Latin America, and Southeast Asia to successfully hedge against domestic sales retractions.

Dreame (追觅科技) Officially Signs Cristiano Ronaldo as Global Brand Ambassador to Deepen Its Global High-End Intelligent Ecosystem Layout

Dreame (追觅科技) officially signed football legend Cristiano Ronaldo as its Global Brand Ambassador, leveraging his premier global commercial appeal to accelerate its transformation from a technology-driven exporter into a super-IP-driven global premium brand across Europe and the Middle East.

Zhuma Innovation completes Angel+ round financing, defining consumer-grade spatial cameras to capture new data for embodied world models

Zhuma Innovation has completed tens of millions of RMB in Angel+ financing and aims to use its consumer-grade spatial camera Pebble as an entry point to convert real-world 3D spatial data into computable and trainable assets for content creation, spatial intelligence, and robotics/embodied AI model training.

Junshi Biosciences Receives NMPA Approval of sNDA for Toripalimab

The study data showed that compared to chemotherapy alone, toripalimab in combination with chemotherapy in the first-line treatment of patients with advanced NSCLC without EGFR/ALK mutations could significantly improve the PFS and the OS of patients with a manageable safety profile regardless of PD-L1 expression status.